High-dose budesonide for early COVID-19 - Authors' reply

Lancet. 2021 Dec 11;398(10317):2147-2148. doi: 10.1016/S0140-6736(21)02449-1.

Authors

F D Richard Hobbs¹, Ly-Mee Yu², Benjamin R Saville³, Mona Bafadhel⁴, Christopher C Butler²

Affiliations

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK. Electronic address: richard.hobbs@phc.ox.ac.uk.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
³ Berry Consultants, Austin, TX, USA.
⁴ Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX2 6GG, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Asthmatic Agents*
Budesonide
COVID-19*
Formoterol Fumarate
Humans
SARS-CoV-2

Substances

Anti-Asthmatic Agents
Budesonide
Formoterol Fumarate

Grants and funding

MC_PC_19079/MRC_/Medical Research Council/United Kingdom